title: An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway.
abstract: High-density lipoprotein (HDL) is believed to play an important role in lowering cardiovascular disease (CVD) risk by mediating the process of reverse cholesterol transport (RCT). Via RCT, excess cholesterol from peripheral tissues is carried back to the liver and hence should lead to the reduction of atherosclerotic plaques. The recent failures of HDL-cholesterol (HDL-C) raising therapies have initiated a re-examination of the link between CVD risk and the rate of RCT, and have brought into question whether all target modulations that raise HDL-C would be atheroprotective. To help address these issues, a novel in-silico model has been built to incorporate modern concepts of HDL biology, including: the geometric structure of HDL linking the core radius with the number of ApoA-I molecules on it, and the regeneration of lipid-poor ApoA-I from spherical HDL due to remodeling processes. The ODE model has been calibrated using data from the literature and validated by simulating additional experiments not used in the calibration. Using a virtual population, we show that the model provides possible explanations for a number of well-known relationships in cholesterol metabolism, including the epidemiological relationship between HDL-C and CVD risk and the correlations between some HDL-related lipoprotein markers. In particular, the model has been used to explore two HDL-C raising target modulations, Cholesteryl Ester Transfer Protein (CETP) inhibition and ATP-binding cassette transporter member 1 (ABCA1) up-regulation. It predicts that while CETP inhibition would not result in an increased RCT rate, ABCA1 up-regulation should increase both HDL-C and RCT rate. Furthermore, the model predicts the two target modulations result in distinct changes in the lipoprotein measures. Finally, the model also allows for an evaluation of two candidate biomarkers for in-vivo whole-body ABCA1 activity: the absolute concentration and the % lipid-poor ApoA-I. These findings illustrate the potential utility of the model in drug development.
authors.affiliation: F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Clinical Pharmacology, Basel, Switzerland.
authors.forename: James
authors.initials: J
authors.lastname: Lu
authors.affiliation: BioQuant, University of Heidelberg, Heidelberg, Germany.
authors.forename: Katrin
authors.initials: K
authors.lastname: Hübner
authors.affiliation: Division of Cardiovascular Genetics, University of Utah, Salt Lake City, Utah, United States of America.
authors.forename: M Nazeem
authors.initials: MN
authors.lastname: Nanjee
authors.affiliation: Utah Foundation for Biomedical Research, Salt Lake City, Utah, United States of America.
authors.forename: Eliot A
authors.initials: EA
authors.lastname: Brinton
authors.affiliation: F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Clinical Pharmacology, Basel, Switzerland.
authors.forename: Norman A
authors.initials: NA
authors.lastname: Mazer
mesh_terms: D064286:ATP Binding Cassette Transporter 1 / Q000378:metabolism; D000465:Algorithms; D001499:Bayes Theorem; D001692:Biological Transport; D015415:Biomarkers / Q000378:metabolism*; D002138:Calibration; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism*; D053480:Cholesterol Ester Transfer Proteins / Q000378:metabolism; D019295:Computational Biology / Q000379:methods; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism*; D008297:Male
chemical_list: D064286:ATP Binding Cassette Transporter 1; D015415:Biomarkers; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008074:Lipoproteins; D002784:Cholesterol